Insider Selling: Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Sells 1,000 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the sale, the chief executive officer owned 436,973 shares of the company's stock, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded down $0.48 during midday trading on Friday, reaching $109.45. The company's stock had a trading volume of 327,049 shares, compared to its average volume of 828,496. The business's fifty day simple moving average is $108.96 and its 200-day simple moving average is $119.07. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a market capitalization of $6.62 billion, a P/E ratio of 14.59, a P/E/G ratio of 4.72 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the previous year, the business posted $2.68 EPS. The company's revenue was down .5% compared to the same quarter last year. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in JAZZ. Versant Capital Management Inc boosted its position in shares of Jazz Pharmaceuticals by 9.4% during the first quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock worth $131,000 after buying an additional 91 shares during the period. Bessemer Group Inc. raised its position in Jazz Pharmaceuticals by 0.3% in the 4th quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock valued at $3,317,000 after buying an additional 92 shares during the last quarter. Kendall Capital Management lifted its stake in Jazz Pharmaceuticals by 1.2% in the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock valued at $989,000 after acquiring an additional 95 shares in the last quarter. Synovus Financial Corp grew its stake in shares of Jazz Pharmaceuticals by 0.5% during the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock worth $2,365,000 after acquiring an additional 100 shares in the last quarter. Finally, Quarry LP grew its stake in shares of Jazz Pharmaceuticals by 6.3% during the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock worth $209,000 after acquiring an additional 100 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on JAZZ shares. Piper Sandler restated an "overweight" rating and set a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Robert W. Baird lowered their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley dropped their price target on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Finally, Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $184.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.